News >

Pegilodecakin Falls Short in Phase III Pancreatic Cancer Trial

Jason M. Broderick @jasoncology
Published: Wednesday, Oct 16, 2019

Maura Dickler, MD, vice president, late phase development, Lilly Oncology

Maura Dickler, MD

Combining the pegylated IL-10 pegilodecakin with FOLFOX (folinic acid, 5-FU, oxaliplatin) chemotherapy did not improve overall survival (OS) as a second-line therapy for patients with metastatic pancreatic cancer, according to topline results from the phase III SEQUOIA trial.1



  1. Lilly announces phase 3 study in patients with metastatic pancreatic cancer did not meet primary endpoint of overall survival. Posted October 16, 2019. Accessed October 16, 2019.
  2. Hecht JR, Naing A, Falchook GS, et al. Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX). Ann Oncol. 2018;29(8 suppl, abstr 1143P). doi: 10.1093/annonc/mdy288.016.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication